Pre-made Ontamalimab benchmark antibody ( Whole mAb, anti-MADCAM1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ontamalimab biosimilar, Whole Mab: Anti-MADCAM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1 in development for the induction and maintenance of clinical remission in patients with ulcerative colitis (UC).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-404-1mg	1mg	3090
GMP-Bios-ab-404-10mg	10mg	Inquiry
GMP-Bios-ab-404-100mg	100mg	Inquiry
GMP-Bios-ab-404-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ontamalimab biosimilar, Whole Mab: Anti-MADCAM1 therapeutic antibody
INN Name	Ontamalimab
Target	MADCAM1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	4hcr:MN:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Pfizer;Takeda
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Crohn's disease;Ulcerative colitis
Development Tech	na